CD30/Ki-1-positive lymphoproliferative disorders of the skin--clinicopathologic correlation and statistical analysis of 86 cases: a multicentric study from the European Organization for Research and ...
SINGAPORE, June 16, 2023 (GLOBE NEWSWIRE) -- Tessa Therapeutics Ltd. (Tessa), a clinical-stage cell therapy company developing next-generation cancer treatments for hematological malignancies and ...
Cells of certain blood cancers such as Hodgkin’s lymphoma carry the protein CD30 on their surface. The molecule is not only an indicator of a few cancers of the immune system but also increases the ...
A recent study explored the efficacy of brentuximab vedotin (BV) in patients with high-CD30–expressing non-Hodgkin lymphoma (NHL) to determine who is most likely to benefit. A recent study explored ...
Please provide your email address to receive an email when new articles are posted on . The introduction of rituximab in the 1990s revolutionized the treatment of CD20+ B-cell lymphomas. Unfortunately ...
Please provide your email address to receive an email when new articles are posted on . Since the discovery of the CD30 molecule in 1982, progress has been made in the treatment and survival outcomes ...
High expression of CD30 and JunB is the hallmark of malignant cells in Hodgkin lymphoma (HL) and anaplastic large cell lymphoma (ALCL). Ligand-independent signaling by CD30 induces JunB, which ...
SINGAPORE, Dec. 12, 2021 (GLOBE NEWSWIRE) -- Tessa Therapeutics Ltd. (Tessa), a clinical-stage cell therapy company developing next-generation cancer treatments for hematological malignancies and ...
The European Commission has extended conditional marketing authorisation for Takeda’s Adcetris to include the treatment of CD30-positive cutaneous T-cell lymphoma (CTCL) following one prior systemic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results